Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 730

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 3
Chunk 730
---
 statements for the valuation of debt and warrants and valuation
of bifurcated derivative liabilities and other financial instruments.

Cash
and Cash Equivalents

Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2024 and 2023, cash and cash equivalents consisted of the following:

 Schedule of Cash and Cash Equivalents

    2024  
    2023 

    December 31, 

    2024  
    2023 
  
    Cash 
    $1,918,941  
    $1,550,098 
  
    Money market funds 
     1,203  
     1,026,318 
  
    Total cash and cash equivalents 
    $1,920,144  
    $2,576,416 

    F-8

Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250,000 per institution. The
amount in excess of the FDIC insurance as of December 31, 2024 was approximately $1.7 million. The Company has not experienced losses
on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to
these deposits is not significant.

Marketable
Securities

Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.

The
marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding
balance of $0
and $2.9 million
as of December 31, 2024 and 2023, respectively. As of the years ended December 31, 2024 and 2023, the Company recognized
interest income of less than $0.1
million and $0.1
million, realized gains of less than $0.1
million and less than $0.1 million,
and unrealized gain of $0
and $0.1
million, respectively.